NZ company develops face recognition for sheep

By Stuart Corner A Dunedin based company, Iris Data Science, aims to develop what it says will be the world’s first sheep facial recognition software, eliminating the need for electronic identification or ear tagging. It will prototype the technology this year after receiving a $40,000 grant from the New Zealand Government’s innovation agency, Callaghan Innovation,…

Suba Engineering ships first laser marker

Sydney’s Suba Engineering has taken another step in its journey from importer to fully fledged product developer and manufacturer with the delivery of its first SubaLaser industrial marker. Suba’s owner Heinz Zimmerman showed off the locally developed marker at his Melbourne office this week (pictured). Zimmerman said: “We showed our SubaLaser marker prototype just over…

$2.3 million in grants announced for SA SMEs in defence industry

Four Sovereign Industrial Capability Priority grants totalling $2.3 million, and all going to South Australian firms, were announced on Tuesday.   The SICP is a program offering between $50,000 and $1 million in dollar-matched funding to SMEs in defence. The successful firms in this round would use their funding to help investment in specialised tools…

Carnegie Mellon team tackles security issues for networked 3D printers

Carnegie Mellon University researchers have developed a tool for identifying and addressing cybersecurity vulnerabilities in networked 3D printers.   In work funded by the Pittsburgh university’s Manufacturing Futures Initiative, Vyas Sekar and Matthew McCormack have created a system to identify a printer’s security vulnerabilities and identify potential routes of attack.    “For example, it can…

Noxopharm reports anti-cancer effects of Veyonda

Sydney anti-cancer treatment company Noxopharm (ASX: NOX) has reported anti-cancer effects of its Veyonda treatment in a small group of patients suffering advanced prostate cancer. The 14 patients’ cancers were metastatic and they had exhausted all treatment options when given Veyonda in association with low-dosage radiation in a single lesion. After six months, cancer progression…